Skip to main content
Premium Trial:

Request an Annual Quote

Genome Therapeutics Reveals Drop in Revenues, Profits for Fourth Quarter

Premium

WALTHAM, Mass.--Genome Therapeutics here has reported financial results for its fiscal year and fourth quarter of 1997 that show a drop in revenues and a net loss, compared to a profit for the same period last year. The company's financial year ended on August 31.

Genome Therapeutics' total revenues for fiscal 1997 were $19.6 million, compared to $21.3 million for fiscal 1996, with a net loss in fiscal 1997 of $11.3 million, or 64 cents per share, compared to net income of $1.9 million, or 11 cents per share, the previous year. However, the loss doesn't include revenues from a newly signed antifungal alliance, multiple database subscriptions, and milestone payments that were expected in fiscal 1997 but which actually occurred in the first few weeks of fiscal 1998, the company's management noted.

The decline in revenues is the result of a reduction in government contract research and grants, as the company refocuses on supporting commercial partnerships, the firm added.

"These results reflect our commitment to build Genome Thera peutics into a fully integrated genomics discovery company that will attract revenue-producing partnerships and alliances," explained Robert Hennessey, Genome Therapeutics' chairman, president, and CEO. "To strengthen our leadership in pathogen genomics and expand our human genomics programs, we have made prudent investments in building our scientific capabilities, especially in the areas of bioinformatics and functional genomics. We will continue to make these investments as needed in the future to maintain our position as a leader in the genomics industry."

Hennessey also noted that Genome Therapeutics has recently launched PathoGenome, which he called "the world's most comprehensive commercial database of genomic information on pathogens," signed an exclusive human genomics partnership for asthma, and extended an existing H. pylori alliance with Astra.

Filed under

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.